Julien Tanniou

Julien Tanniou

Auto-generated profile, based on publicly available information

Julien Tanniou

Quinten Health Paris France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2016 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
JTJulien Tanniou
Julien Tanniou
ITIngeborg van der Tweel
Ingeborg van der Tweel
STSteven Teerenstra
Steven Teerenstra
KRKit C. B. Roes
Kit C. B. Roes
It is well recognized that treatment effects may not be homogeneous across the study population. Subgroup analyses constitute a fundamental step in the assessment of evidence from confirmatory (Phase III) clinical trials, where conclusions for the overall study population might not hold. Subgroup analyses can have different and distinct purposes, requiring specific design and analysis solutions. It is relevant to evaluate methodological developments in subgroup analyses against these purposes to guide health care professionals and regulators as well as to identify gaps in current methodology. We defined four purposes for subgroup analyses: (1) Investigate the consistency of treatment effects across subgroups of clinical importance, (2) Explore the treatment effect across different subgroups within an overall non-significant trial, (3) Evaluate safety profiles limited to one or a few subgroup(s), (4) Establish efficacy in the targeted subgroup when included in a confirmatory testing strategy of a single trial. We reviewed the methodology in line with this “purpose-based” framework. The review covered papers published between January 2005 and April 2015 and aimed to classify them in none, one or more of the aforementioned purposes. In total 1857 potentially eligible papers were identified. Forty-eight papers were selected and 20 additional relevant papers were identified from their references, leading to 68 papers in total. Nineteen were dedicated to purpose 1, 16 to purpose 4, one to purpose 2 and none to purpose 3. Seven papers were dedicated to more than one purpose, the 25 remaining could not be classified unambiguously. Purposes of the methods were often not specifically indicated, methods for subgroup analysis for safety purposes were almost absent and a multitude of diverse methods were developed for purpose (1). It is important that researchers developing methodology for subgroup analysis explicitly clarify the objectives of their methods in terms that can be understood from a patient’s, health care provider’s and/or regulator’s perspective. A clear operational definition for consistency of treatment effects across subgroups is lacking, but is needed to improve the usability of subgroup analyses in this setting. Finally, methods to particularly explore benefit-risk systematically across subgroups need more research.

30 September 2016 in Statistical Methods in Medical Research
Verified
Journal Article
Closed access
JTJulien Tanniou
Julien Tanniou
ITIngeborg van der Tweel
Ingeborg van der Tweel
STSteven Teerenstra
Steven Teerenstra
KRKit Cb Roes
Kit Cb Roes
In drug development and drug licensing, it sometimes occurs that a new drug does not demonstrate effectiveness for the full study population, but there appears to be benefit in a relevant, pre-defined subgroup. This raises the question, how strong the evidence from such a subgroup is, and which confirmatory testing strategies are the most appropriate ones. Hence, we considered the type I error and the power of a subgroup result in a trial with non-significant overall results and of suitable replication strategies. In the case of a single trial, the inflation of the overall type I error is substantial and can be up to twice as large, especially in relatively small subgroups. This also increases to the risk of starting a replication trial that should not be done, if such a second trial is not already available. The overall type I error is almost controlled by using an appropriate replication strategy. This confirms the required cautious interpretation of promising subgroups, even in the case that overall trial results were perceived to be close to significance.

19 February 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
CJCe Jiang
Ce Jiang
CBCéline Beji
Céline Beji
SZSonia Zebachi
Sonia Zebachi
GHGhinwa Y. Hayek
Ghinwa Y. Hayek
ACAysun Cetinyurek‐Yavuz
Aysun Cetinyurek‐Yavuz
JTJulien Tanniou
Julien Tanniou
The decision‐making process in drug development involves “go/no‐go” decisions, particularly at the transition from early to late‐stage trials. While the decisions are solely made by drug developers, they must take into account the perspectives of multiple stakeholders—such as regulatory agencies, HTA bodies, payers, patients, and ethics committees—to ensure well‐informed and robust decision‐making. These perspectives influence key considerations, including resource allocation, risk mitigation, regulatory compliance, etc. To support this process, quantitative methodologies, including Bayesian and hybrid frequentist‐Bayesian approaches, have been introduced to improve decision‐making. However, these methodologies often do not fully account for the diverse priorities and needs of all stakeholders. This scoping review examines criteria and methods used in decision‐making at the phase II to III transition, with a focus on broadening the probability of success (PoS) concept beyond efficacy alone. Our review explores PoS for different success definitions, such as regulatory approval, market access, financial viability, and competitive performance. Key themes include decision criteria selection, trial design optimization, utility‐based approaches, financial metrics, and multi‐stakeholder considerations in decision‐making. Our findings highlight both the limitations of current methodologies and potential paths forward, including the integration of real‐world data (RWD) and advanced analytics. This work complements a companion manuscript by Cetinyurek‐Yavuz et al. (2025) providing a detailed review of PoS methodologies focused solely on efficacy, specifically PoS for achieving statistical significance in phase III studies, including definitions, terminologies, and analytical approaches. Together, these studies provide a foundation for advancing late‐stage trial decisions toward a more balanced, data‐driven, and stakeholder‐aligned approach.

15 May 2017 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
PDF file
JTJulien Tanniou
Julien Tanniou
ITIngeborg van der Tweel
Ingeborg van der Tweel
STSteven Teerenstra
Steven Teerenstra
KRKit C.B. Roes
Kit C.B. Roes

2 July 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
SZSonia Zebachi
Sonia Zebachi
JTJulien Tanniou
Julien Tanniou
EBElisabeth Bakker
Elisabeth Bakker
SVSieta de Vries
Sieta de Vries
RBRossella Di Bidino
Rossella Di Bidino
JMJeverson Moreira
Jeverson Moreira
The potential of real‐world data (RWD), particularly from patient registries, has been increasingly recognized over the last decade by academia, regulators, and health technology assessment (HTA) bodies for its role in assessing a product's effectiveness and supporting regulatory submissions. The selection of an appropriate RWD source is of primary concern, since the success of regulatory processes depends on the quality and relevance of the data. In more recent years, EMA and FDA have released extensive guidance on the use of RWD to produce evidence. Simultaneously, public and private research institutions have proposed structured frameworks developed to guide stakeholders in evaluating and selecting “fit‐for‐purpose” RWD sources. This scoping review provides an overview of these structured frameworks, identifying nine key tools, including the Registry Evaluation and Quality Standards Tool (REQueST) and the Structured Process to Identify Fit‐For‐Purpose Data (SPIFD2). Each framework is briefly described, followed by a comparative analysis of the criteria they assess. These criteria relate to dimensions such as study design, data reliability, data relevance, ethical considerations, and practical factors such as cost and feasibility. Our findings indicate that while these frameworks offer robust tools for ensuring the suitability of RWD sources, each has unique strengths and limitations depending on the specific context of use. By providing a comprehensive understanding of these frameworks, this review aims to assist stakeholders in identifying and/or evaluating and/or selecting the most appropriate RWD sources for generating high‐quality evidence for regulatory and HTA purposes.

24 January 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
AYAysun Cetinyurek Yavuz
Aysun Cetinyurek Yavuz
MFMuhammad Bergas Nur Fayyad
Muhammad Bergas Nur Fayyad
CJCe Jiang
Ce Jiang
FBFlorie Brion Bouvier
Florie Brion Bouvier
CBCeline Beji
Celine Beji
LRLaura Rodwell
Laura Rodwell
Drug development is a lengthy process with considerable uncertainty at each milestone. Several trials are needed to progress to confirmatory evaluation and establish a positive benefit–risk balance. One of the critical milestones is the decision to progress to phase III based on phase II trial results. Use of probability of success is becoming standard in pharmaceutical companies to support this decision. However, the lack of consistency in terminology makes it difficult to assess the comparative value of different approaches. By leveraging the availability of high‐quality external data (e.g., real‐world data, historical clinical trial data, etc.), probability of success‐based procedures may further improve decision‐making. We performed a scoping review of approaches to calculate the probability of success of a phase III trial depending on the available data sources and the availability of specific endpoints. Calculation of probability of success is relatively straightforward if data for the primary endpoint of the phase III trial are also available in phase II trials. Often, phase II trials are based on biomarker or surrogate outcomes, due to challenges associated with study duration and required sample size. Probability of success‐based procedures as reviewed can incorporate external data sources, for example, from clinical trials testing the same or similar drug or real‐world data on the targeted population—optimizing the calculation of probability of trial success and the projected drug candidate value. We conclude the paper by reflecting on alternative approaches and ideas for uses within pharmaceutical companies and academia.